E3 Ligase Ligands

Pomalidomide 4'-alkylC6-azide is a cereblon (CRBN) ligand that facilitates selective protein targeting via the recruitment of the CRBN protein. It serves as a key component in the development of PROTACs (Proteolysis Targeting Chimeras), enabling targeted degradation of specific proteins. This reagent is essential for research in targeted protein degradation and the modulation of cellular pathways critical for disease mechanisms.

Pomalidomide-C6-COOH is a cereblon (CRBN) ligand derived from pomalidomide, designed for the specific recruitment of CRBN proteins. This compound serves as a vital building block for the development of PROTACs by enabling the conjugation of CRBN with various proteins via a linker. Its utility in targeted protein degradation makes it a valuable reagent for research applications in cellular signaling and therapeutic interventions.

Pomalidomide-5-C8-NH2 hydrochloride is a CRBN ligand derived from Pomalidomide. This compound facilitates the recruitment of the cereblon (CRBN) protein, enabling the design of targeted protein degradation strategies. It can be conjugated with a suitable linker to create PROTACs, which are valuable tools in therapeutic applications for modulating protein levels in various biological contexts.

CRBN ligand-895-PEG2-N3 is a synthetic E3 ligase ligand-linker conjugate designed to facilitate the development of PROTACs. This compound plays a crucial role in the targeted degradation of proteins by linking to E3 ligases, enhancing the specificity and efficacy of degradation processes. It serves as a valuable tool for researchers investigating protein modulation and therapeutic applications in targeted protein degradation strategies.

E3 Ligase Ligand-linker Conjugate 195 is a conjugate that targets cereblon (CRBN) through its ligand component. This compound facilitates the development of Proteolysis Targeting Chimeras (PROTACs) by providing a functional linker necessary for targeted protein degradation. It is suitable for research applications investigating novel therapeutic strategies in protein modulation and degradation pathways.

VH032-C6-NH-Boc is a Boc-modified ligand that targets the von Hippel-Lindau (VHL) E3 ligase, facilitating the recruitment of VHL proteins. Under acidic conditions, it readily deprotection occurs, allowing its direct utilization in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound serves as a crucial intermediate in developing PROTACs utilizing VHL ligands, thereby advancing research in targeted protein degradation.

(S,R,S)-AHPC-CO-C9-NH2 is a Von Hippel-Lindau (VHL) ligand that serves as a crucial building block for the synthesis of E3 ligase ligands utilized in the development of PROTACs (Proteolysis Targeting Chimeras). This compound enhances the understanding of protein degradation pathways and enables targeted protein modulation, making it a valuable tool for researchers investigating targeted therapies in cancer and other diseases.

Pomalidomide-C11-NH2 is a Pomalidomide derivative that functions as a ligand for the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling targeted protein degradation applications through PROTAC technology. Its utility in the development of targeted therapeutics offers significant potential for advancing cancer research and treatment strategies.

Pomalidomide-5-C5-NH2 hydrochloride is a cereblon (CRBN) ligand derived from Pomalidomide, designed to facilitate the recruitment of the CRBN protein. This compound serves as a crucial component for the development of PROTACs that promote targeted protein degradation. Its unique structural modifications enhance its ability to engage with CRBN, enabling innovative research into therapeutic applications in cancer and other diseases.

CDLI-5 is a cereblon (CRBN) degrader-linker conjugate designed for the synthesis of cereblon degrader antibody conjugates (cDACs). This compound enables targeted protein degradation through the recruitment of E3 ligases to specific substrates, facilitating effective modulation of protein levels. CDLI-5 serves as a valuable tool in research applications focused on targeted therapies and the development of novel anticancer strategies.

VH032-C2-NH-Boc is a Boc-modified ligand targeting the von Hippel-Lindau (VHL) E3 ligase, facilitating the recruitment of VHL proteins. Upon exposure to acidic conditions, it readily removes the protecting group, enabling its application in the direct synthesis of PROTAC molecules. This compound serves as an essential intermediate in developing PROTACs that utilize VHL ligands, offering valuable utility in targeted protein degradation research.

VH032-C3-Boc is a Boc-modified derivative of VH032, functioning as a ligand for the E3 ligase von Hippel-Lindau (VHL). Under acidic conditions, VH032-C3-Boc enables the removal of the protective group, facilitating direct utilization in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound serves as an essential intermediate for developing VHL-based PROTACs, contributing to advancements in targeted protein degradation research.

β-Naphthoflavone-CH2-OH is a selective ligand for the arylhydrocarbon receptor (AhR) E3 ligase. This compound serves as a critical component in the design of targeted protein degradation strategies, such as PROTACs and SNIPERs, by linking to specific protein ligands to facilitate the recruitment of the AhR E3 ligase complex. Its ability to induce ubiquitination-mediated degradation of oncoproteins makes it a valuable tool in cancer research and drug discovery.

CRBN ligand-8-O-C6-NH2 is an E3 ligase ligand-linker conjugate that targets the cereblon (CRBN) E3 ubiquitin ligase, facilitating targeted protein degradation. This compound serves as a critical component in the synthesis of PROTAC ERα Degrader-11, thus aiding in the study of estrogen receptor-alpha (ERα) modulation and its associated cellular pathways. Researchers can utilize CRBN ligand-8-O-C6-NH2 for advancing the development of targeted therapeutic strategies in cancer and other diseases influenced by ERα signaling.

VH 032 amide-PEG6-amine hydrochloride is a functionalized ligand for the von Hippel-Lindau (VHL) E3 ligase, specifically designed for PROTAC (Proteolysis Targeting Chimera) development. This compound features an E3 ligase ligand conjugated to a PEG6 moiety, facilitating the incorporation of terminal amines for coupling with target protein ligands. VH 032 amide-PEG6-amine hydrochloride is essential for advancing research in targeted protein degradation and drug development strategies.

VH032-C4-NH-Boc is a Boc-modified variant of the VH032 compound that serves as a ligand for the von Hippel-Lindau (VHL) protein, facilitating the recruitment of VHL in E3 ligase applications. Upon exposure to acidic conditions, the Boc protecting group is removed, enabling its use in the synthesis of PROTAC molecules. This compound is a critical intermediate for developing PROTAC strategies that leverage VHL ligands for targeted protein degradation research.

VH032-PEG2-NH-BOC is a Boc-modified VH032 compound that functions as a ligand for E3 ligase von Hippel-Lindau (VHL). This reagent facilitates the recruitment of VHL proteins and can be deprotected under acidic conditions, enabling its direct application in PROTAC molecule synthesis. VH032-PEG2-NH-BOC serves as a crucial intermediate for generating PROTACs utilizing VHL ligands, thereby advancing research in targeted protein degradation and therapeutic applications.

CRBN Ligand-Linker Conjugate 2 is an E3 ligand-linker conjugate designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted degradation of specific proteins by harnessing the ubiquitin-proteasome system. It has been utilized in the development of FIP22, a highly selective IRAK4 PROTAC degrader, which demonstrates potential therapeutic activity against atopic dermatitis. Researchers can leverage this conjugate for advancements in targeted protein degradation strategies.

VH032-O-C2-NH-Boc is a Boc-modified derivative of VH032, functioning as a ligand for the E3 ubiquitin ligase von Hippel-Lindau (VHL). This compound facilitates the recruitment of VHL proteins and is valuable in the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules. The Boc protective group can be removed under acidic conditions, allowing for efficient integration into PROTAC development and research applications focused on targeted protein degradation.

Lenalidomide 4'-PEG1-azide is a lenalidomide-derived azide designed for use in click chemistry applications. This compound features an azide moiety that engages in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, facilitating efficient bioconjugation. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-containing partners, making it valuable for various chemical biology studies and the development of novel therapeutics.

Lenalidomide 4'-PEG2-azide is a Lenalidomide-derived ligand that targets Cereblon, facilitating the recruitment of CRBN protein. This compound can be utilized to create PROTACs by linking it to various proteins, thereby enabling targeted protein degradation and advancing research in drug development and cellular regulation. Its use is relevant in the study of E3 ligase-mediated pathways and therapeutic strategies in oncology and immunology.

VH 101 phenol-alkylC6-amine dihydrochloride is a functionalized ligand targeting the von-Hippel-Lindau (VHL) protein, facilitating the development of PROTACs. This compound promotes selective protein degradation by engaging E3 ligases, making it a valuable tool for studying protein turnover and cellular regulation. Its application in chemical biology can aid in understanding the mechanisms of targeted protein degradation and potential therapeutic interventions.

PPACK dihydrochloride is a potent and selective irreversible inhibitor of thrombin. It serves as an alternative anticoagulant to lithium heparin for blood gas and electrolyte analyses in whole blood. Additionally, PPACK dihydrochloride inhibits plasminogen activator (rt-PA), preventing its binding to plasma protease inhibitors. This compound also reduces plasmin-induced endothelial permeability and morphological changes in bovine aortic endothelial cell monolayers, making it suitable for investigations in thrombosis-related research.

Thalidomide-5-F-6-piperidinylpiperazin is a ligand for E3 ligase-linker conjugates and plays a crucial role in the synthesis of PROTAC CDK9 degrader-9. This compound facilitates targeted protein degradation, making it a valuable tool for studies on cellular signaling pathways and protein regulation. Researchers can utilize this reagent to explore therapeutic approaches in cancer and other diseases by modulating the activity of CDK9 and related targets.